Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16929775 | 0.81 | MAPK1 (0.39) | MEN1KMT2AMAPK1KMOLMNA | |
| SCHEMBL16929742 | 0.77 | MAPK1 (0.41) | MAPK1KMO | |
| SCHEMBL30612059 | 0.75 | TUBB4A (0.34) | NOTUM | |
| SCHEMBL26107235 | 0.75 | TUBB4A (0.34) | NOTUM | |
| SCHEMBL17666340 | 0.75 | SMN1; SMN2 (0.34) | MEN1KMT2AKMOSMN1; SMN2P2RX7 | |
| SCHEMBL16972308 | 0.74 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2TRPM5 | |
| SCHEMBL7573919 | 0.74 | HRH4 (0.32) | MEN1KMT2ASMN1; SMN2TRPM5 | |
| SCHEMBL17844744 | 0.73 | MAPK1 (0.44) | MAPK1NOTUMTRPM5 | |
| SCHEMBL17661901 | 0.71 | GABRA1 (0.41) | MEN1KMT2AMAPK1 | |
| SCHEMBL18886874 | 0.71 | NOTUM (0.32) | MAPK1NOTUMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-3421458-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica NV (BE) | 2019-01-02 | — | — | EP | disclosed |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| EP-2970157-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | US | disclosed |
| US-9562053-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| EP-2970157-A2 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159061-A2 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
| US-20140275172-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | MEN1 4390/4885KMT2A 2759/4885MAPK1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.